The Next Neuren

There, I said it

Just as NEU has found many uses for their major pipeline drugs, it makes sense that PPL-1 and its variants could prove effective across a broad spectrum of cancers and potentially other applications.

Looking at all these new analogues, variations of the original PPL-1, there is no knowing where this could take PAA.

The fact this started out as sheep dip and is now a candidate in cancer treatment leaves me asking 'what else?

Just like NEU with big money nearby, it makes sense that PAA doesn't hold the same capital dillution profile as many other juniors in development.

From corporate transactions, to clinical results I can see a thickness of announcements throughout the development of PAA

This is all blue sky pie of course, but I think we have more than Disallowed here

(tried to upload a picture of a grotesque cheerleader but alas couldn't figure it out)